VYEPTI

VYEPTI is a prescription medicine for the preventive treatment of migraine in adults. Its active ingredient is eptinezumab-jjmr, and it is administered by intravenous (IV) infusion. The brand’s patient website helps people understand the treatment, explore clinical study results, and learn what to expect during an infusion. It also provides information about possible side effects and important safety considerations, alongside links to the full Prescribing Information and Patient Information.

VYEPTI resources are designed to support conversations between patients and healthcare providers. Visitors can create a personalized discussion guide, locate an infusion provider, and connect with registered nurses for answers to questions. The site also offers information about insurance coverage, financial assistance, copay support, and a migraine community featuring patient stories and downloadable resources. VYEPTI is described as a treatment given in four 30-minute infusions per year, with migraine-prevention benefits shown in clinical studies to last three months. The site emphasizes that individual results may vary and encourages patients to discuss whether treatment is appropriate with their healthcare provider.